Abstract:Mitochondrial GCN5L1 regulates proliferation and tumorigenesis in hepatocellular carcinoma (HCC) via glutamine metabolism. Deletion of general control of amino acid synthesis 5 like 1 (GCN5L1) enhances both glutaminase 1 (GLS1) and glutaminase 2 (GLS2) activities by altering acetylation and oligomerisation. Compound 968 inhibits GLS2 to suppress diethylnitrosamine (DEN)‐ and carbon tetrachloride (CCl4)‐induced HCC development. Our study suggests that targeting glutaminase or mTORC1 activity could be a potential therapeutic treatment for HCC expressing lower levels of GCN5L1. Background Glutaminolysis is a critical metabolic process that promotes cancer cell proliferation, including hepatocellular carcinoma (HCC). Delineating the molecular control of glutaminolysis could identify novel targets to ameliorate this oncogenic metabolic pathway. Here, we evaluated the role of general control of amino acid synthesis 5 like 1 (GCN5L1), a regulator of mitochondrial protein acetylation, in modulating the acetylation and activity of glutaminase to regulate HCC development. Methods Cell proliferation was determined by MTT, 2D and soft agar clone formation assays and orthotopic tumour assays in nude mice. GLS1/2 acetylation and activities were measured in cells and tumours to analyse the correlation with GCN5L1 expression and mTORC1 activation. Results Hepatic GCN5L1 ablation in mice markedly increased diethylnitrosamine (DEN)‐induced HCC, and conversely, the transduction of mitochondrial‐restricted GCN5L1 protected wild‐type mice against HCC progression in response to DEN and carbon tetrachloride (CCl4) exposure. GCN5L1–depleted HepG2 hepatocytes enhanced tumour growth in athymic nude mice. Mechanistically, GCN5L1 depletion promoted cell proliferation through mTORC1 activation. Interestingly, liver–enriched glutaminase 2 (GLS2) appears to play a greater role than ubiquitous and canonical tumour–enriched glutaminase 1 (GLS1) in promoting murine HCC. Concurrently, GCN5L1 promotes acetylation and inactivation of both isoforms and increases enzyme oligomerisation. In human HCC tumours compared to adjacent tissue, there were variable levels of mTORC1 activation, GCN5L1 levels and glutaminase activity. Interestingly, the levels of GCN5L1 inversely correlated with mTORC1 activity and glutaminase activity in these tumours. Conclusions Our study identified that glutaminase activity, rather than GLS1 or GLS2 expression, is the key factor in HCC development that activates mTORC1 and promotes HCC. In the Kaplan–Meier analysis of liver cancer, we found that HCC patients with high GCN5L1 expression survived longer than those with low GCN5L1 expression. Collectively, GCN5L1 functions as a tumour regulator by modulating glutaminase acetylation and activity in the development of HCC.

Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth

Licensing instead of fueling: Glutamine synthetase promotes mitotic progression via a non-metabolic mechanism

Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1

Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma

Targeting GLS1 to cancer therapy through glutamine metabolism

Glutamine Synthetase as a Therapeutic Target for Cancer Treatment

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

O-GlcNAcylation Promotes Pancreatic Tumor Growth by Regulating Malate Dehydrogenase 1

Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer.

Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth

N-Myc Promotes Glutamine Anaplerosis And Aggressive Tumor Progression Through Direct Gls2 Activation

Myc Promotes Glutaminolysis in Human Neuroblastoma Through Direct Activation of Glutaminase 2

Activation of Polyamine Catabolism Promotes Glutamine Metabolism and Creates a Targetable Vulnerability in Lung Cancer

Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis

Glutaminase Sustains Cell Survival Via the Regulation of Glycolysis and Glutaminolysis in Colorectal Cancer.

GLS1 Filament Formation Facilitates Glutamine Deprivation Induced Cell Death

Reprogramming Of Proline And Glutamine Metabolism Contributes To The Proliferative And Metabolic Responses Regulated By Oncogenic Transcription Factor C-Myc

Oncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation.

Glutamine addiction in tumor cell: oncogene regulation and clinical treatment

Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma

Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5